{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T06:03:59Z","timestamp":1789365839214,"version":"build-2803163510"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Upper tract urothelial carcinoma (UTUC) carries a high risk of postoperative recurrence; however, the decline in renal function following radical nephroureterectomy often limits the use of cisplatin-based chemotherapy. While the combination of disitamab vedotin and PD-1 inhibitors has demonstrated antitumor activity in advanced urothelial carcinoma, evidence regarding its use as postoperative adjuvant therapy remains limited. This study retrospectively identified patients with UTUC who underwent radical resection with R0 margins and had no distant metastasis prior to treatment, and who subsequently received disitamab vedotin combined with a PD-1 inhibitor due to unsuitability for or refusal of platinum-based chemotherapy. A total of seven patients were included; all were male, with a median age of 65 years. Pathological analysis confirmed pure urothelial carcinoma without histological variants in all cases. Four patients exhibited high-risk features (\u2265pT3 stage or lymph node positivity); all cases showed HER2 expression of IHC 2+ or 3+ and PD-L1 expression &amp;lt;1%. All patients completed four cycles of the combination therapy. With a median follow-up of 22.3\u00a0months, three recurrences and two deaths occurred, including three cases of local recurrence. The 12-month postoperative recurrence-free survival (RFS) rate was 71.4%, and the median RFS had not yet been reached. Treatment-related adverse events (TRAEs) of any grade and Grade \u22653 TRAEs occurred in four and two patients, respectively; no Grade 4\u20135 adverse events or treatment-related deaths were observed. These results provided a preliminary description of the practical feasibility and observed safety of this regimen in a specific cohort of postoperative UTUC patients; however, given the very small sample size and the lack of a control group, no conclusions regarding therapeutic efficacy could be drawn, and further prospective studies are required for evaluation.<\/jats:p>","DOI":"10.3389\/fphar.2026.1952518","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:39:20Z","timestamp":1789364360000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Disitamab vedotin combined with PD-1 inhibitors for postoperative adjuvant therapy in upper tract urothelial carcinoma: a retrospective exploratory case series"],"prefix":"10.3389","volume":"17","author":[{"given":"Yongbao","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Urology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaishan","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Urology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewen","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Urology, Longyan First Affiliated Hospital of Fujian Medical University","place":["Longyan, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruochen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixuan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Urology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Urology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Urology, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated People\u2019s Hospital of Fujian University of Traditional Chinese Medicine","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"IMvigor010 study group. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jaad.2012.02.010","article-title":"Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0","volume":"67","author":"Chen","year":"2012","journal-title":"J. Am. Acad. Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/JU.0000000000004475","article-title":"A phase 2 study of tislelizumab as neoadjuvant treatment of cisplatin-ineligible high-risk upper tract urothelial carcinoma","volume":"213","author":"Huang","year":"2025","journal-title":"J. Urol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-targeting antibody\u2013drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.eururo.2025.08.012","article-title":"Neoadjuvant chemotherapy for high-risk localized upper tract urothelial carcinoma: final long-term outcomes from a phase 2 clinical trial and an expanded cohort","volume":"89","author":"Jayalath","year":"2026","journal-title":"Eur. Urol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.urolonc.2025.03.023","article-title":"Comparative efficacy of adjuvant chemotherapy and immunotherapy after radical surgery for upper tract urothelial carcinoma: a systematic review and meta-analysis","volume":"43","author":"Liu","year":"2025","journal-title":"Urol. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.eururo.2025.02.023","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: summary of the 2025 update","volume":"87","author":"Masson-Lecomte","year":"2025","journal-title":"Eur. Urol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00262-025-04154-5","article-title":"The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world study","volume":"74","author":"Ng","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1011885","DOI":"10.3389\/fonc.2022.1011885","article-title":"HER2 expression in urothelial carcinoma, a systematic literature review","volume":"12","author":"Scherrer","year":"2022","journal-title":"Front. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-x","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin. Trials"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/jco.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/nejmoa2511648","article-title":"RC48-C016 trial investigators. Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00345-016-1871-x","article-title":"HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","journal-title":"World J. Urol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3760\/cma.j.cn112152-20210809-00597","article-title":"Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China","volume":"43","year":"2021","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1809094","DOI":"10.3389\/fimmu.2026.1809094","article-title":"Adjuvant disitamab vedotin plus PD-1 blockade and gemcitabine\/cisplatin in high-risk upper tract urothelial carcinoma: a two-stage real-world comparative study","volume":"17","author":"Wang","year":"2026","journal-title":"Front. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/jco.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.euo.2025.09.015","article-title":"Endoscopic thulium laser ablation with disitamab vedotin and immunotherapy in high-risk upper tract urothelial carcinoma: a prospective pilot study of a novel kidney-sparing strategy","volume":"8","author":"Ye","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1952518\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:39:21Z","timestamp":1789364361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1952518\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":19,"alternative-id":["10.3389\/fphar.2026.1952518"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1952518","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"1952518"}}